ClinicalTrials.gg
RecruitingNCT07950774PNIRS in VLBWIUpdated Nov 20, 2026

Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants

An observational study in Neonatal Respiratory Distress, sponsored by University of Stellenbosch. Recruiting at 1 site in South Africa. Open to participants aged 26 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Stellenbosch · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
26 Weeks to 32 Weeks
Sex
All
01

Study summary

This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.

The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.

The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.

Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration

Read the detailed description

Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)

Objectives:

Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.

Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)

This will be an investigator-initiated, prospective, observational trial.

Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.

All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment

Study Procedures

Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.

Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.

Monitoring Devices

  1. Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral

    • Pulmonary NIRS - Pulmonary sensors will be placed in a horizontal position at the 4th intercostal space area (nipple line) on the left and right hemithorax
    • Cerebral NIRS - Cerebral sensor will be placed on the right of the forehead
  2. Vital sign monitoring: Synchronized vital signs (heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2) (Nellcor) will be monitored using a multi-parameter monitor (Mindray UMEC15, Shenzhen, China).
  3. Non-invasive cardiac output monitoring: Haemodynamic monitoring will occur using the ICON Core from Osypka Medical. This provides non-invasive monitoring of numerous haemodynamic parameters, including cardiac output, stroke volume, systemic vascular resistance, cardiac contractility and thoracic fluid content. ICON sensors will be placed in standard positions on the forehead, neck arm and leg for monitoring.

Intervention procedures

1. Ultrasound:

  1. Lung ultrasound (LUS) will be performed after placement of the NIRS (within the first 6 hours of life) and daily. LUS will also be performed prior to any SRT. alculated. Video-clips will be stored and reviewed by blinded co-investigators.
  2. Cranial ultrasound (CUS) will be performed on day 1,2 and 3 to monitor for any intraventricular haemorrhage as well as to measure cerebral blood flow velocities, which may affect crSO2 values.
  3. Point-of-care echocardiography (POC-echo) will be performed to determine cardiac function, cardiac output, and the presence of a patent ductus arteriosus, size, flow velocity and pattern, which may affect prSO2 and crSO2 values. Standard echocardiography techniques will be used and will be performed daily on day 1,2 and 3 of life.

Trial duration

The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.

Discontinuation of study intervention

Monitoring of the infant will stop, and sensors will be removed if:

  • Requested by mother
  • Requested by treating clinician
  • Thoracic intervention required (e.g. intercostal drainage for pneumothorax)
  • Surgery required (e.g. laparotomy for focal intestinal perforation)
  • Sensors interfere with medical management

Withdrawal from study

At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.

Duration of study participation

Study participation for each infant is:

  • Initiated within the first 3 hours of life
  • Monitoring until 72 hours after birth
  • Follow up from 72 hours until final discharge from hospital or in-hospital death.

Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)

02

Conditions studied

  • Neonatal Respiratory Distress

Keywords

  • respiratory distress syndrome
  • preterm infant
03

In context

Pulmonary Atelectasis

378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.

This study's planned enrollment of 100 is above the median of 78 across 101 observational studies indexed under Pulmonary Atelectasis.

Browse Pulmonary Atelectasis studies →

Lead sponsor

University of Stellenbosch is the lead sponsor of 35 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
26 Weeks to 32 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infant ≤ 32 weeks gestational age and/ or birth weight ≤ 1800g
  • Infant diagnosed with respiratory distress syndrome requiring CPAP after birth
  • Infant born at the research institution

Exclusion criteria

Exclusion Criteria:

  • Infants ≤ 26 weeks gestational age or \<750g
  • Infants with other causes of respiratory distress
  • Infants with antenatal or postnatally diagnosed structural pulmonary abnormalities
  • Infants with known or suspected chromosomal abnormalities
  • Infants with other congenital structural abnormalities that may require surgery in the first 72 hours after birth
  • Infants with known or suspected congenital infections including congenital syphilis, cytomegalovirus or toxoplasmosis
  • Infants intubated after birth or requiring intubation and invasive ventilation immediately after birth
  • Infants with a 5-minute Apgar ≤ 5
  • Instillation of surfactant prior to enrollment
  • Infants not expected to survive the first 72 hours after birth
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • CPAP only

    Infants receiving CPAP only

    Device: Pulmonary near-infra-red spectroscopy

  • SRT

    Infants receiving CPAP plus surfactant

    Device: Pulmonary near-infra-red spectroscopy

Interventions

  • DevicePulmonary near-infra-red spectroscopy

    Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

06

What researchers measure

Primary outcomes

  1. PRSO2 values

    Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life

    Time frame: 72 hours

Secondary outcomes

  1. SRT prediction

    Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS

    Time frame: 72 hours

  2. Compare prSo2 & lung ultrasound between groups

    Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups

    Time frame: 72 hours

  3. Compare prSo2 & OSI between groups

    Determine correlation between prSO2 and OSI between groups

    Time frame: 72 hours

  4. Compare prSo2 & SOPI between groups

    Determine correlation between prSO2 and SOPI between groups

    Time frame: 72hrs

Other outcomes

  1. PRSO2/CUS

    Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups

    Time frame: 72hours

  2. Longitudinal analysis SOPI

    longitudinal comparison of SOPI between groups

    Time frame: 72 hours

  3. Longitudinal OSI

    longitudinal comparison of OSI between groups

    Time frame: 72 hours

  4. Longitudinal thoracic fluid content (TFC)

    longitudinal comparison of TFC between groups

    Time frame: 72 hours

  5. Longitudinal CI

    longitudinal comparison of cardiac index between groups

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dani C, Miselli F, Zini T, Scarponi D, Luzzati M, Sarcina D, Fusco M, Dianori F, Berardi A. Measurement of lung oxygenation by near-infrared spectroscopy in preterm infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 2024 Jun;59(6):1631-1637. doi: 10.1002/ppul.26955. Epub 2024 Mar 5. PubMed 38441387 ↗
  • Ozdemir FE, Alan S, Aliefendioglu D. The diagnostic value of pulmonary near-infrared spectroscopy in the early distinction of neonatal pneumonia from transient tachypnea of the newborn. Pediatr Pulmonol. 2023 Nov;58(11):3271-3278. doi: 10.1002/ppul.26656. Epub 2023 Aug 30. PubMed 37646118 ↗

Individual participant data

Plan to share: No — Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 58 non-industry observational studies under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 12 months is close to that.

Counting every sponsor, half of 58 studies reached it within 11 months; a quarter within 6 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950774
Lead sponsor
University of Stellenbosch
Collaborators
Medtronic
Responsible party
Lizelle Van Wyk (Clinical Professor, University of Stellenbosch) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Lizelle Van Wyk, PhD
Contact
lizelle@sun.ac.za
+27219389506

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion